classifying xylazine as a schedule III controlled drug.

SB 465 classifies xylazine - a veterinary sedative sometimes misused in illicit drug mixtures - as a Schedule III controlled substance under New Hampshire law. This change permanently places xylazine in Schedule III (a category for drugs with moderate abuse potential and accepted medical uses) via statutory amendment, overriding the commissioner’s authority to schedule it through rulemaking. It directly affects individuals and entities handling xylazine in New Hampshire, including healthcare providers, law enforcement, and pharmacies. The bill takes effect January 1, 2027, with no estimated state revenue or expenditure impact.